Wuhan YZY Biopharma – HK$176 Million IPO

Hong Kong – September 25, 2023 – Cooley advised Wuhan YZY Biopharma, a biotechnology company dedicated to developing bispecific antibody-based therapies to treat cancer-associated complications, cancer and age-related ophthalmologic diseases, on its HK$176 million global initial public offering –subject to the exercise of the overallotment option. Partners Ethan Jin and Yiming Liu led the Cooley team.

Wuhan YZY Biopharma offered a total of 11,001,200 H shares, priced at $16 per H share. The listing began trading on the Hong Kong Stock Exchange on September 25, 2023, under the stock code 2496.

China Securities International served as sole sponsor, overall coordinator, joint global coordinator, joint bookrunner and joint lead manager for the global offering. CSCI, Guotai Junan, CCBI, BOCI, TFI Securities, China Galaxy International, Livermore and Futu Securities acted as the international and/or Hong Kong underwriters for the global offering.

About Cooley LLP

Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.

Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.